These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 9501687)
21. Some aspects of the management of hypertension II. Special considerations. Rowe WS Med J Aust; 1975 Mar; 1(10):307-8. PubMed ID: 1128344 [No Abstract] [Full Text] [Related]
22. [Are all antihypertensive drugs renoprotective?]. Wolf S; Risler T Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950 [TBL] [Abstract][Full Text] [Related]
23. [Antihypertensive therapy in patients with 4 and 5 stage chronic kidney disease undergoing periodic dialysis]. Goicoechea MA Nefrologia; 2004; 24 Suppl(6):161-71, 187-235. PubMed ID: 15696905 [No Abstract] [Full Text] [Related]
25. [Therapy of arterial hypertension]. Di Perri T Clin Ter; 1974 Sep; 70(5):409-24. PubMed ID: 4423620 [No Abstract] [Full Text] [Related]
26. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Cohuet G; Struijker-Boudier H Pharmacol Ther; 2006 Jul; 111(1):81-98. PubMed ID: 16288809 [TBL] [Abstract][Full Text] [Related]
27. Hypertension in end-stage renal disease: target values, methods of measurement and drug therapy. Zoccali C J Nephrol; 2002; 15(2):199-201. PubMed ID: 12018640 [No Abstract] [Full Text] [Related]
28. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Griffin KA; Bidani AK Clin J Am Soc Nephrol; 2006 Sep; 1(5):1054-65. PubMed ID: 17699327 [TBL] [Abstract][Full Text] [Related]
29. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease? Pisoni R; Remuzzi G J Nephrol; 2000; 13(3):228-31. PubMed ID: 10928301 [TBL] [Abstract][Full Text] [Related]
30. [Antihypertensive treatment in the elderly]. Maki K Nihon Rinsho; 2006 Aug; 64 Suppl 6():342-7. PubMed ID: 16983771 [No Abstract] [Full Text] [Related]
31. [Hypertension and 24-hours blood pressure monitoring in kidney diseases]. Csiky B; Wittmann I; Nagy J Orv Hetil; 2004 Feb; 145(7):323-6. PubMed ID: 15049046 [TBL] [Abstract][Full Text] [Related]
32. [Arterial hypertension in patients with nephroptosis]. Kurbangaleev SM; Almazov VA; Maslova NP; Protasov AA; Kotenko AD Sov Med; 1975 Jul; (7):26-31. PubMed ID: 1216045 [No Abstract] [Full Text] [Related]
33. [The kidneys and hypertension]. Hausberg M; Mann J; Kühn K Dtsch Med Wochenschr; 2008 Sep; 133(37):1853-6. PubMed ID: 18770487 [TBL] [Abstract][Full Text] [Related]
34. [Is the treatment of arterial hypertension a nephroprotector? Effects may be different based on the class of anti-hypertensive agents used]. Chauveau D; Martinez F Rev Prat; 1993 Jan; 43(2):187-91. PubMed ID: 8502937 [No Abstract] [Full Text] [Related]
35. [Renal hypertension in urological patients]. Gütgemann A; Vahlensieck W; Albrecht D Dtsch Med J; 1968 Apr; 19(8):286-91. PubMed ID: 5728723 [No Abstract] [Full Text] [Related]
37. Pathologic basis and treatment considerations in chronic kidney disease-related hypertension. Sica D; Carl D Semin Nephrol; 2005 Jul; 25(4):246-51. PubMed ID: 16202697 [TBL] [Abstract][Full Text] [Related]
38. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan]. Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535 [TBL] [Abstract][Full Text] [Related]
39. [Vascular impact of anti-hypertensive treatment and renal protection]. Mogensen CE Curr Med Res Opin; 2005; 21 Suppl 5():S23-8. PubMed ID: 16197649 [TBL] [Abstract][Full Text] [Related]
40. Hypertension in human renal disease. Brown MA; Whitworth JA J Hypertens; 1992 Aug; 10(8):701-12. PubMed ID: 1325500 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]